Schambye HT[au] - Search Results

Year	Number of Results
1992	2
1993	2
1994	3
1995	2
1996	1
1997	1
2003	1
2006	1
2022	0

1

Effect of different buffers on the biocompatibility of CAPD solutions.

Schambye HT. Schambye HT. Perit Dial Int. 1996;16 Suppl 1:S130-6. Perit Dial Int. 1996. PMID: 8728179 Review.

2

Transcriptome analysis of FSH and FSH variant stimulation in granulosa cells from IVM patients reveals novel regulated genes.

Perlman S, Bouquin T, van den Hazel B, Jensen TH, Schambye HT, Knudsen S, Okkels JS. Perlman S, et al. Among authors: schambye ht. Mol Hum Reprod. 2006 Mar;12(3):135-44. doi: 10.1093/molehr/gah247. Epub 2006 Mar 23. Mol Hum Reprod. 2006. PMID: 16556681

3

Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor.

Perlman S, Schambye HT, Rivero RA, Greenlee WJ, Hjorth SA, Schwartz TW. Perlman S, et al. Among authors: schambye ht. J Biol Chem. 1995 Jan 27;270(4):1493-6. doi: 10.1074/jbc.270.4.1493. J Biol Chem. 1995. PMID: 7829475 Free article.

4

Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations.

Perlman S, Costa-Neto CM, Miyakawa AA, Schambye HT, Hjorth SA, Paiva AC, Rivero RA, Greenlee WJ, Schwartz TW. Perlman S, et al. Among authors: schambye ht. Mol Pharmacol. 1997 Feb;51(2):301-11. doi: 10.1124/mol.51.2.301. Mol Pharmacol. 1997. PMID: 9203636

5

[Non-peptide antagonists to angiotensin II receptors. A review].

Schambye HT, Hjorth SA, Schwartz TW. Schambye HT, et al. Ugeskr Laeger. 1993 Nov 1;155(44):3558-62. Ugeskr Laeger. 1993. PMID: 8236577 Review. Danish.

6

Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone.

Perlman S, van den Hazel B, Christiansen J, Gram-Nielsen S, Jeppesen CB, Andersen KV, Halkier T, Okkels S, Schambye HT. Perlman S, et al. Among authors: schambye ht. J Clin Endocrinol Metab. 2003 Jul;88(7):3227-35. doi: 10.1210/jc.2002-021201. J Clin Endocrinol Metab. 2003. PMID: 12843169

7

Mutations in transmembrane segment VII of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists.

Schambye HT, von Wijk B, Hjorth SA, Wienen W, Entzeroth M, Bergsma DJ, Schwartz TW. Schambye HT, et al. Br J Pharmacol. 1994 Oct;113(2):331-3. doi: 10.1111/j.1476-5381.1994.tb16899.x. Br J Pharmacol. 1994. PMID: 7834178 Free PMC article.

8

Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor.

Schambye HT, Hjorth SA, Weinstock J, Schwartz TW. Schambye HT, et al. Mol Pharmacol. 1995 Mar;47(3):425-31. Mol Pharmacol. 1995. PMID: 7700239

9

Bicarbonate- versus lactate-based CAPD fluids: a biocompatibility study in rabbits.

Schambye HT, Flesner P, Pedersen RB, Hardt-Madsen M, Chemnitz J, Christensen HK, Detmer A, Pedersen FB. Schambye HT, et al. Perit Dial Int. 1992;12(3):281-6. Perit Dial Int. 1992. PMID: 1511044

10

Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors.

Schambye HT, Hjorth SA, Bergsma DJ, Sathe G, Schwartz TW. Schambye HT, et al. Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7046-50. doi: 10.1073/pnas.91.15.7046. Proc Natl Acad Sci U S A. 1994. PMID: 8041743 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results